11 completed, 2 recruiting, 1 enrolling by invitation, 1 terminated. 16 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 11, Recruiting 2, Enrolling by invitation 1, Terminated 1, Unknown 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow Dosage Forms: new trials by email Literature Review of Dosage Forms trials Research Report on Dosage Forms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab - Polyarticular Course Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Recruiting | Duke University | 400 | 2026-01-09 | 2026-10-21 |
| Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment., A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC - Metabolic Syndrome, Cardiovascular Disease (CKD) | Phase 3 | Enrolling by invitation | Guangdong Provincial Hospital of Traditional Chinese Medicine | 530 | 2025-04-24 | 2025-06-13 |
| Cellulitis Optimal Antibiotic Treatment Flucloxacillin Only Product in Oral Dose Form, Placebo Only Product in Oral Dose Form - Cellulitis of Leg | Phase 3 | Recruiting | University of Southampton | 334 | 2023-08-29 | 2026-05-15 |
| Voxelotor Neurocognitive Function Study Voxelotor Only Product in Oral Dose Form, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 1 | 2022-06-24 | 2024-05-02 |
| Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 24 | 2022-06-10 | 2026-08-26 |
| Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery? IV Medications, placebo - Colo-rectal Cancer, Anesthesia | Phase 3 | Completed | Thomas Jefferson University | 90 | 2022-05-27 | 2024-04-09 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) Lisdexamfetamine Dimesylate (Medication), Placebo - Loss-of-control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 16 | 2022-01-02 | 2026-08-06 |
| EXHIT ENTRE Comparative Effectiveness Trial Extended Release Buprenorphine, Treatment as Usual - Substance Use Disorder, Opioid Use Disorder, Moderate | Phase 2 / Phase 3 | Completed | Gavin Bart | 344 | 2021-08-09 | 2026-11-06 |
| Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Hydroxychloroquine Only Product in Oral Dose Form - Sars-CoV2, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | University of Malaga | 1930 | 2020-09-01 | 2020-09-29 |
| Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid | Phase 3 | Completed | International Vaccine Institute | 1800 | 2020-02-04 | 2021-08-27 |
| Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer Dronabinol in Oral Dosage Form, Placebo in Oral Dosage Form - Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 109 | 2019-12-16 | 2025-04-10 |
| Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care Bedaquiline Oral Tablet, Linezolid Oral Tablet, Delamanid in Oral Dosage Form - Tuberculosis, Pre-XDR-TB | Phase 3 | Completed | Wits Health Consortium (Pty) Ltd | 402 | 2019-08-22 | 2024-08-28 |
| A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation Paliperidone palmitate 3 month formulation (PP3M) - Schizophrenia | Phase 3 | Completed | Janssen-Cilag Ltd. | 306 | 2016-04-28 | 2025-04-27 |
| Adherence, Improvement Measure (AIM) System SMS medication adherence, No SMS adherence reminder - Patient Compliance, AIDS | Phase 3 | Completed | University of California, San Francisco | 99 | 2010-08-01 | 2013-11-20 |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) clofarabine (IV formulation), placebo, cytarabine - Acute Myelogenous Leukemia | Phase 3 | Completed | Genzyme, a Sanofi Company | 326 | 2006-08-01 | 2014-04-14 |
| Magnetic Brain Stimulation for the Treatment of Adult Depression Prefrontal rTMS, Antidepressant Regimen, Sham Stimulation - Depression | Phase 2 / Phase 3 | Completed | Medical University of South Carolina | 190 | 2005-02-01 | 2018-12-28 |
Obesity (2) · Overweight (2) · Acquired Immunodeficiency Syndrome (1) · Anemia, Sickle Cell (1) · Arthritis, Juvenile (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Cerebrovascular Disorders (1) · Colonic Neoplasms (1) · Coronavirus Infections (1) · Depression (1) · Extensively Drug-Resistant Tuberculosis (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Follicular (1) · Metabolic Syndrome (1)
Yale University (2) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Duke University (1) · Gavin Bart (1) · Genzyme, a Sanofi Company (1) · Guangdong Provincial Hospital of Traditional Chinese Medicine (1) · International Vaccine Institute (1) · Janssen-Cilag Ltd. (1) · Medical University of South Carolina (1) · Pfizer (1) · Thomas Jefferson University (1) · University of California, San Francisco (1) · University of Malaga (1) · University of Southampton (1) · Wits Health Consortium (Pty) Ltd (1)
United States (9) · Germany (4) · France (2) · Italy (2) · Netherlands (2) · United Kingdom (2) · Austria (1) · Canada (1) · China (1) · Croatia (1) · Denmark (1) · Greece (1) · Israel (1) · Malaysia (1) · Philippines (1)
Carlos Grilo, PhD (1) · Felix Keil, Prof.MD (1) · Francesca M Conradie (1) · Gavin Bart, MD,PhD (1) · James Kahn, MD (1) · Josefina C Carlos, MD (1) · Juan C Morilla-Herrera, PhD (1) · Mark S. George, MD (1) · Valentina Ivezaj, Ph.D. (1)
PMID 20439832, PMID 22585697, PMID 23769413, PMID 24176437, PMID 35186258, PMID 35664443, PMID 39623502, PMID 42341301, PMID 42582064
R01DK126637 (2), 1RC1MH088341 (1), 2008 (1), 2015 (1), 5UG1DA040316-05 (1), R01MH069887 (1)